Elevar Therapeutics Names Wade Smith Chief Financial Officer SALT LAKE CITY, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...

Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...

Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial Results of open-label, multicenter study will be presented during a poster session at ASCO on June 6 Rivoceranib represents a potential new treatment option for patients with R/M ACC who have...

Elevar Therapeutics Names Paul Friel Chief Commercial Officer, Michael Palucki VP of Manufacturing SALT LAKE CITY, May 23, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...